Kura Oncology (KUR) Price & Analysis

Compare

6 Followers

KUR Stock Chart & Stats

€7.27

-€0.16(-1.94%)

At close: Jan 08 4:00 PM EST

€7.27

-€0.16(-1.94%)

Day’s Range― - ―

52-Week Range€4.68 - €10.78

Previous CloseN/A

Volume0.00

Average Volume (3M)148.00

Market Cap

$637.39M

Enterprise Value€703.86M

Total Cash (Recent Filing)$549.66M

Total Debt (Recent Filing)$19.47M

Price to Earnings (P/E)―

Beta0.86

Next Earnings

Apr 30, 2026

EPS Estimate

-0.69

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.79

Shares Outstanding87,017,520

10 Day Avg. Volume0

30 Day Avg. Volume148

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)5.23

Price to Sales (P/S)13.50

P/FCF Ratio-12.89

Enterprise Value/Market Cap1.10

Enterprise Value/Revenue6.77

Enterprise Value/Gross Profit6.98

Enterprise Value/Ebitda-3.19

Forecast

1Y Price Target

$24.29

Price Target Upside234.17% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

EPS Forecast (FY)-2.84

Revenue Forecast (FY)$112.73M

Bulls Say, Bears Say

Bulls Say

Clinical Data ReadoutsMultiple upcoming clinical data readouts for ziftomenib and other pipeline candidates create opportunities for positive validation that could expand label use and boost prescribing if results confirm current efficacy signals.

Commercial Launch And Payer CoverageBroad early payer coverage combined with initial Komzifti sales suggests solid launch momentum that could support sequential revenue growth as physician adoption expands.

Financial Position And FundingA strong cash balance together with anticipated collaboration milestone payments is expected to fund pivotal frontline development through a top-line trial readout, reducing near-term reliance on equity financing.

Bears Say

Competitive PressureManagement's view that the market can support multiple competitors implies rising competitive pressure that could erode Komzifti's market share over time.

Dependence On Future Clinical OutcomesBroader commercial success depends on results and enrollment in ongoing late‑stage trials, so delays or disappointing outcomes in those studies could materially weaken growth expectations.

Payer Access RestrictionsImplementation of step edits by several large commercial plans requiring an alternative before Komzifti may limit patient access and slow uptake in important payer accounts.

Kura Oncology News

Kura Oncology price target raised to $30 from $29 at BofA

BofA raised the firm’s price target on Kura Oncology (KURA) to $30 from $29 and keeps a Buy...

13h ago

KURA

Kura Oncology price target lowered to $36 from $38 at Wedbush

Wedbush lowered the firm’s price target on Kura Oncology (KURA) to $36 from $38 and keeps an Outperform...

14h ago

KURA

Kura Oncology reports inducement grants under Nasdaq listing rule

Kura Oncology (KURA) announced that on March 2, 2026, the Compensation Committee of the Company’s Board of Directors...

14h ago

KURA

Kura Oncology reports Q4 EPS (92c), consensus (49c)

Reports Q4 revenue $17.34M, consensus $35.45M. As of December 31, 2025, Kura had $667.2M in cash, cash equivalents...

2d ago

KURA

Kura Oncology management to meet with Citizens

Group Dinner Meeting with Management in Miami on March 11 hosted by Citizens. Published first on TheFly –...

3d ago

KURA

Kura Oncology reports inducement grants under Nasdaq listing rule

Kura Oncology (KURA) announced that on February 2, 2026, the Compensation Committee of the Company’s Board of Directors...

29d ago

KURA

Kura Oncology Earnings Call Highlights Comzifty Launch

Kura Oncology (($KURA)) has held its Q4 earnings call. Read on for the main highlights of the call....

1d ago

KURA

Early Komzifti Traction and Clinical Catalysts Underpin Buy Rating and 2028 Growth Outlook

TD Cowen analyst Phil Nadeau has maintained their bullish stance on KURA stock, giving a Buy rating today....

1d ago

KURA

Kura Oncology: Early KOMZIFTI Launch Momentum, Robust AML Data, and Strong Cash Runway Underpin Buy Rating

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Kura Oncology. The associated price target...

1d ago

KURA

KURA Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Kura Oncology (KURA) is scheduled to report 4th quarter earnings on 03/05/2026, before the market opens. Regarding Q4...

4d ago

KURA

Kura Oncology price target lowered to $29 from $30 at BofA

BofA analyst Jason Zemansky lowered the firm’s price target on Kura Oncology (KURA) to $29 from $30 and...

1M ago

KURA

Kura Oncology Tightens Governance with Amended Bylaws

The latest update is out from Kura Oncology ( ($KURA) ). On January 28, 2026, Kura Oncology’s board...

1M ago

KURA

3 ‘Strong Buy’ Biotech Stocks to Buy Today, 1/13/2026, According to Top Analysts

Looking for top-rated stocks to buy now? Based on recent analyst updates, the three companies below have all...

2M ago

WVE

KURA

Kura Oncology price target lowered to $20 from $25 at Leerink

Leerink lowered the firm’s price target on Kura Oncology (KURA) to $20 from $25 and keeps an Outperform...

2M ago

KURA

KUR FAQ

What was Kura Oncology’s price range in the past 12 months?

Kura Oncology lowest stock price was €4.68 and its highest was €10.78 in the past 12 months.

What is Kura Oncology’s market cap?

Kura Oncology’s market cap is $637.39M.

When is Kura Oncology’s upcoming earnings report date?

Kura Oncology’s upcoming earnings report date is Apr 30, 2026 which is in 54 days.

How were Kura Oncology’s earnings last quarter?

Kura Oncology released its earnings results on Mar 05, 2026. The company reported -€0.792 earnings per share for the quarter, missing the consensus estimate of -€0.55 by -€0.242.

Is Kura Oncology overvalued?

According to Wall Street analysts Kura Oncology’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kura Oncology pay dividends?

Kura Oncology does not currently pay dividends.

What is Kura Oncology’s EPS estimate?

Kura Oncology’s EPS estimate is -0.69.

How many shares outstanding does Kura Oncology have?

Kura Oncology has 87,017,520 shares outstanding.

What happened to Kura Oncology’s price movement after its last earnings report?

Kura Oncology reported an EPS of -€0.792 in its last earnings report, missing expectations of -€0.55. Following the earnings report the stock price went up 1.366%.

Which hedge fund is a major shareholder of Kura Oncology?

Currently, no hedge funds are holding shares in DE:KUR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Kura Oncology Stock Smart Score

Neutral

Fundamentals

Return on Equity

-94.82%

Trailing 12-Months

Asset Growth

-29.05%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kura Oncology

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Kura Oncology (KUR) Earnings & Revenues

Historic Earnings Reports

KUR Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call presents a predominantly positive commercial and clinical story: FDA approval, immediate product shipments, rapid payer coverage (~84% of private payers within 90 days), beneficial payer step edits, patent protection to 2044, robust sales force deployment, and multiple near‑term clinical catalysts across AML and the FTI program. Financially, the company is investing heavily in commercialization and development, which widened operating losses and reduced collaboration revenue year-over-year; cash remains substantial (~$667M) with anticipated milestone support through top-line Phase 3 readout in 2028. Overall, strengths in launch execution, access, patent protection, and a data-rich development plan outweigh near‑term financial pressures and uncertainties around duration of therapy and reliance on milestone timing.View all DE:KUR earnings summaries

KUR Stock 12 Month Forecast

Average Price Target

€24.29

▲(234.17% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"€3","11":"€11","19":"€19","27":"€27","35":"€35"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34.3984232,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€34.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.293886385,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€24.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.75936928,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€13.76</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,11,19,27,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.252,9.3401864,11.428372800000002,13.516559200000001,15.604745600000001,17.692932000000003,19.781118400000004,21.869304800000002,23.957491200000003,26.045677600000005,28.133864000000006,30.222050400000004,32.310236800000006,{"y":34.3984232,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.252,8.562914337307692,9.873828674615385,11.184743011923077,12.495657349230768,13.806571686538462,15.117486023846155,16.428400361153844,17.739314698461538,19.05022903576923,20.361143373076924,21.672057710384614,22.982972047692307,{"y":24.293886385,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.252,7.752566867692307,8.253133735384615,8.753700603076922,9.25426747076923,9.754834338461539,10.255401206153845,10.755968073846153,11.256534941538462,11.757101809230768,12.257668676923075,12.758235544615385,13.258802412307691,{"y":13.75936928,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.256,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.996,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.644,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.94,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.805,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.176,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.788,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.38,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.966,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.07,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.612,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.252,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >